Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.
As of close of business last night, Catalyst Pharmaceuticals Inc’s stock clocked out at $22.69, down -3.08% from its previous closing price of $23.41. In other words, the price has decreased by -$3.08 from its previous closing price. On the day, 1.18 million shares were traded. CPRX stock price reached its highest trading level at $23.15 during the session, while it also had its lowest trading level at $22.64.
Ratios:
To gain a deeper understanding of CPRX’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 4.04 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 11.89. For the most recent quarter (mrq), Quick Ratio is recorded 6.40 and its Current Ratio is at 6.62. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In the most recent recommendation for this company, Robert W. Baird on February 04, 2025, initiated with a Outperform rating and assigned the stock a target price of $28. On November 18, 2024, Stephens started tracking the stock assigning a Overweight rating and target price of $35. On March 14, 2024, Citigroup started tracking the stock assigning a Buy rating and target price of $27.Citigroup initiated its Buy rating on March 14, 2024, with a $27 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Nov 26 ’25 when Del Carmen Jeffrey sold 10,983 shares for $23.33 per share. The transaction valued at 256,244 led to the insider holds 3,962 shares of the business.
Del Carmen Jeffrey bought 10,983 shares of CPRX for $256,247 on Nov 26 ’25. On Nov 12 ’25, another insider, Elsbernd Brian, who serves as the Officer of the company, bought 40,000 shares for $22.70 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CPRX now has a Market Capitalization of 2788882176 and an Enterprise Value of 2101879040. As of this moment, Catalyst’s Price-to-Earnings (P/E) ratio for their current fiscal year is 13.24, and their Forward P/E ratio for the next fiscal year is 12.70. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 1.12. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.82 while its Price-to-Book (P/B) ratio in mrq is 3.04. Its current Enterprise Value per Revenue stands at 3.635 whereas that against EBITDA is 7.087.
Stock Price History:
The Beta on a monthly basis for CPRX is 0.68, which has changed by 0.045140505 over the last 52 weeks, in comparison to a change of 0.12607694 over the same period for the S&P500. Over the past 52 weeks, CPRX has reached a high of $26.58, while it has fallen to a 52-week low of $19.05. The 50-Day Moving Average of the stock is 6.24%, while the 200-Day Moving Average is calculated to be 2.93%.
Shares Statistics:
It appears that CPRX traded 1.47M shares on average per day over the past three months and 1206290 shares per day over the past ten days. A total of 123.26M shares are outstanding, with a floating share count of 110.68M. Insiders hold about 9.95% of the company’s shares, while institutions hold 81.06% stake in the company. Shares short for CPRX as of 1763078400 were 8487702 with a Short Ratio of 5.76, compared to 1760486400 on 8421577. Therefore, it implies a Short% of Shares Outstanding of 8487702 and a Short% of Float of 8.81.
Earnings Estimates
The market rating for Catalyst Pharmaceuticals Inc (CPRX) is a result of the insights provided by 4.0 analysts actively involved in the assessment.The consensus estimate for the next quarter is $0.59, with high estimates of $0.64 and low estimates of $0.53.
Analysts are recommending an EPS of between $2.7 and $2.11 for the fiscal current year, implying an average EPS of $2.5. EPS for the following year is $2.58, with 4.0 analysts recommending between $2.7 and $2.47.
Revenue Estimates
In. The current quarter, 7 analysts expect revenue to total $141.49M. It ranges from a high estimate of $149.64M to a low estimate of $136.14M. As of. The current estimate, Catalyst Pharmaceuticals Inc’s year-ago sales were $141.82MFor the next quarter, 7 analysts are estimating revenue of $142.4M. There is a high estimate of $144.18M for the next quarter, whereas the lowest estimate is $139.5M.
A total of 7 analysts have provided revenue estimates for CPRX’s current fiscal year. The highest revenue estimate was $586.02M, while the lowest revenue estimate was $572.52M, resulting in an average revenue estimate of $577.87M. In the same quarter a year ago, actual revenue was $491.73MBased on 7 analysts’ estimates, the company’s revenue will be $619.51M in the next fiscal year. The high estimate is $633.67M and the low estimate is $595.52M.
